GC Biopharma brings its proven legacy of excellence in plasma technology to the US through GC Biopharma USA, Inc. Headquartered in Teaneck, NJ, GC Biopharma USA extends our expertise and commitment as a global leader. We have recently launched our next-generation IVIG 10% liquid formulation, ALYGLO™ (Immune Globulin Intravenous, Human-stwk) for Adults- 17 and older, with Primary Humoral Immunodeficiency (PI). As our business grows, we are committed to meeting our customers' needs and building a platform dedicated to our mission and vision. MISSION Devoted to improving the healthy lives of people VISION A global leader in the healthcare industry GC Biopharma specializes in rare disease drugs and is one of the top pharmaceutical manufacturers of plasma products, which are distributed in more than 50 countries. Our past success is the foundation of our future.
External link for GC Biopharma USA, Inc.
Teaneck, NJ 07666, US
It's Day 1 of the IgNS conference and we're recognizing all the healthcare professionals who go the extra step for their patients with primary immunodeficiency (PI). If you're on the front lines of administering IG treatment, we want to hear your insight. Select your answer or share a different response in the comments below. #GCBiopharmaUSA #GCBiopharma #IgTherapy #IgNS
This content isn’t available here
Access this content and more in the LinkedIn app
Our GC Biopharma USA team is comprised of Ig industry veterans. Every year about this time we’re buzzing with curiosity and anticipation. This conference is a must for learning, networking, and getting critical updates on the latest developments, trends, changes in the field. But this year, we’re especially excited. Look for us at booth 100, and you’ll soon see why.
We’re excited for this year’s IgNS National Conference, October 17-20. If you’re attending, stop by booth 100 to see why. We also hope you will join us for a 60-minute breakfast symposium Advancing the IVIG Manufacturing Process With Cation Exchange (CEX) Chromatography on Saturday, October 19, 2024, starting at 8am EST. Hosted by a panel of seasoned experts who each bring a unique perspective. •Ryan Dorfman, Ph.D., is a seasoned expert in pharmaceutical product development, analytical method development, and the manufacturing of reagents and custom collection devices. His vast technical expertise spans multiple disciplines, including protein biochemistry, enzymology, blood coagulation, and analytical method development. •Dr. Stacey Ness is currently serving on the Medical Affairs team at GC Biopharma USA. She brings to us significant experience in specialty pharmacy and in the clinical management of chronic diseases and has special interest in working with patient advocacy and support groups. •Suzanne Strasters, MSN-FNP, IgCN is a Nurse Practitioner with extensive experience in clinical nursing, specializing in Ig infusion therapies and providing clinical education to nurses, clinical staff and patients on various Ig therapies. Currently, Suzanne is serving as the Head of Clinical Education for GC Biopharma USA. We’ll be sharing information about our latest therapy including safety, efficacy, and indication, as well as best practices for administration. We hope to see you in Washington DC.
Great news! Our abstract has been accepted for poster presentation at the National Association of Specialty Pharmacy (NASP) 2024 Annual Meeting & Expo. NASP is October 6-9, 2024, at the Gaylord Opryland Resort & Convention Center in Nashville, TN. More than 1,700 specialty pharmacy industry professionals will be there, eager to learn, share best practices and network. If you’re attending, please stop by to see us at booth #513 and join us for an interactive Q&A session on Tuesday, October 8 from 2:00 PM – 3:00 PM CT in the Poster Hall. Presented by Stacey Ness, PharmD, CSP, IgCP, MSCS, AAHIVP Ness, PharmD, IgCP, CSP, MSCS, AAHIVP. Attendees who review the posters on display in the exhibit hall can earn home study continuing education credit. Instructions for credit redemption will be made available online during the conference. We hope to see you there.